$92.24
-5.32-5.45%
Last update: Oct 30, 4:56 PM
Kiniksa Pharmaceuticals International PLC
KNSANASDAQ
Kiniksa Pharmaceuticals (KNSA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Kiniksa Pharmaceuticals (KNSA) last issued guidance on October 27, 2026 for fiscal year 2026. The company guided revenue in the range of $1.04B - $1.05B for the period.
Compared to prior guidance, Kiniksa Pharmaceuticals raised its revenue forecast from a prior range of $980M - $995M.
Kiniksa Pharmaceuticals has issued 8 guidance updates between February 25, 2025 and October 27, 2026. During this period, the company raised its outlook 7 times, reflecting management's growing confidence in business performance.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.33 | $0.30 | $0.16 | $0.35 |
| Actual | $0.56 | $0.30 | $0.27 | $0.17 |
| Surprise | +69.7% | 0.00% | +68.8% | -51.4% |
| Revenue | ||||
| Estimate | $260.4M | $226.7M | $205.6M | $200.9M |
| Actual | $286.0M | $243.6M | $214.3M | $202.1M |
| Surprise | +9.82% | +7.47% | +4.23% | +0.60% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.36 | $0.41 | $0.33 | $0.42 |
| Revenue | ||||
| Consensus | $303.4M | $305.3M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 27, 2026 | $0.56 | $0.33 | 69.7 % |
| Q2 | Jul 28, 2026 | $0.30 | $0.30 | 0.00 % |
| Q1 | Apr 28, 2026 | $0.27 | $0.16 | 68.8 % |
| Q4 | Feb 24, 2026 | $0.17 | $0.35 | -51.4 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 27, 2026 | $285.97M | $260.39M | 9.82 % |
| Q2 | Jul 28, 2026 | $243.60M | $226.66M | 7.47 % |
| Q1 | Apr 28, 2026 | $214.30M | $205.59M | 4.23 % |
| Q4 | Feb 24, 2026 | $202.13M | $200.93M | 0.60 % |
